Therapeutic effect of intracoronary versus intravenous bolus tirofiban in elderly patients with acute coronary syndrome
10.3760/cma.j.issn.0254-9026.2011.06.008
- VernacularTitle:老年急性冠状动脉综合征患者替罗非班冠状动脉和静脉用药的疗效比较
- Author:
Chunhua LI
;
Tiemin HU
;
Yida ZHANG
;
Ying ZHANG
;
Ruitian HOU
;
Jie ZHAO
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Angioplasty,transluminal,percutaneous coronary;
Platelet aggregation inhibitors
- From:
Chinese Journal of Geriatrics
2011;30(6):467-471
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the therapeutic effect of intracoronary versus intravenous bolus tirofiban on myocardial perfusion and major cardiovascular events (MACE) in elderly patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and explore the optimal route of tirofiban application. Methods From July 2009 to July 2010, 120 NSTE-ACS patients undergoing percutaneous coronary intervention (PCI ) were consecutively enrolled in this study. They were randomly divided into two groups: intracoronary (60 cases) versus intravenous (60 cases) bolus tirofiban. Thrombolysis in myocardial infarction (TIMI) flow, TIMI myocardial perfusion grade (TMPG) and MACE 30 days after PCI were observed. Results The incidence of TIMI flow and TMPG 3 grade in intracoronary group were higher than in intravenous group [53(88.3%) vs. 38(63.3%); 53(88.3%) vs. 40(66.7%), respectively, both P＜0.05]. However, MACE incidence and bleeding complications during hospital 30 days after PCI had no significant difference between the two groups [1 (1.7%) vs. 0; 3(5.0%) vs. 5(8.3%)], which were not statistically significant (P＞0.05). Conclusions Intracoronary bolus tirofiban before PCI more effectively increases coronary blood flow and myocardium blush than intravenous route in elderly NSTE-ACS patients.
